Expertise in
16
conditions

Dr. Yousef N. Zakharia

Hematology Oncology | Hematology | Oncology
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
 (2089.0 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
Mayo Clinic Arizona
13400 E Shea Blvd, 
Scottsdale, AZ 
 (2089.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Yousef Zakharia is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Zakharia is highly rated in 16 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Melanoma, Bladder Cancer, and Orchiectomy. Dr. Zakharia is currently accepting new patients.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Mayo Clinic Hospital
University Of Iowa Hospital & Clinics
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Sanford Health
  •  Wellmark
  •  Medica
  •  Humana

Locations

MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment Status: Recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Enrollment Status: Terminated
Publish Date: November 27, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
Cabozantinib and Pembrolizumab As a Front-line Therapy for Advanced Metastatic Melanoma
Cabozantinib and Pembrolizumab As a Front-line Therapy for Advanced Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drug: Ga-68 PSMA-HBED-CC PET
Study Phase: Phase 2/Phase 3
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients
Enrollment Status: Completed
Publish Date: February 15, 2024
Intervention Type: Drug
Study Drug: Ga-68 PSMA-HBED-CC PET
Study Phase: Phase 2/Phase 3
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drug: Ga-68 Prostate-Specific Membrane Antigen-HBED-CC PET
Study Phase: Phase 2/Phase 3
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Enrollment Status: Unknown
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Enrollment Status: Terminated
Publish Date: July 01, 2022
Intervention Type: Drug
Study Phase: Phase 1
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Guadecitabine, Durvalumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 05, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 16 Less Clinical Trials

120 Total Publications

Clinical and Genomic Features of Androgen Indifferent Prostate Cancer.
Clinical and Genomic Features of Androgen Indifferent Prostate Cancer.
Journal: International journal of molecular sciences
Published: December 12, 2024
Similar Doctors
Expertise in
27
conditions
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology
Expertise in
27
conditions
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tanios Bekaii-Saab is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Bekaii-Saab is highly rated in 27 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and Pancreatectomy. Dr. Bekaii-Saab is currently accepting new patients.

Expertise in
25
conditions
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology
Expertise in
25
conditions
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology

Banner Cancer Center Specialists LLC

1900 N Higley Rd, 
Gilbert, AZ 
 (14.4 mi)
480-543-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Madappa Kundranda is a Hematologist and an Oncologist in Gilbert, Arizona. Dr. Kundranda is highly rated in 25 conditions, according to our data. His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Kundranda is currently accepting new patients.

Expertise in
17
conditions
Dr. Christina S. Wu
Hematology Oncology | Oncology | Hematology
Expertise in
17
conditions
Dr. Christina S. Wu
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Wu is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Wu is highly rated in 17 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Pancreaticoduodenectomy, and Liver Embolization. Dr. Wu is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile